14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PATH vs VRNS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, UiPath, Inc. (PATH) is the stronger overall head-to-head candidate over Varonis Systems, Inc. (VRNS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PATH carries a Unified Composite Score of 56.8/100 (HOLD) at $13.24 (17.4x Forward P/E, 9.4% operating margin), whereas VRNS carries 53.4/100 (HOLD) at $48.99 (114.9x Forward P/E, -22.5% operating margin).
Technical & Structure Timing Caution: PATH is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.8); meanwhile VRNS trades in a Markup technical trend (CONSOLIDATION options phase, RSI 55.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Software - Infrastructure value chain with $5.7B market capitalization and -22.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PATH vs VRNS Key Questions & Quantitative Answers
As of Nov 16, 2026, UiPath, Inc. (PATH) is the stronger overall head-to-head candidate over Varonis Systems, Inc. (VRNS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). PATH carries a Unified Composite Score of 56.8/100 (HOLD) at $13.24 (17.4x Forward P/E, 9.4% operating margin), whereas VRNS carries 53.4/100 (HOLD) at $48.99 (114.9x Forward P/E, -22.5% operating margin). Technical & Structure Timing Caution: PATH is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.8); meanwhile VRNS trades in a Markup technical trend (CONSOLIDATION options phase, RSI 55.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VRNS leads the Growth & Scale pillar: PATH posts +13.4% YoY revenue growth and N/A YoY earnings growth on $1.72B TTM revenue (82.6% gross margin, 9.4% operating margin), compared with VRNS at +17.3% YoY revenue growth and +0.0% YoY earnings growth on $716M TTM revenue (76.3% gross margin, -22.5% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), PATH cumulative revenue shifted +373.5% while VRNS shifted +148.0%. In operating R&D and SG&A reinvestment, PATH deploys 73.2% of Rev ($1.26B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VRNS.
PATH screens cheaper on headline valuation multiples. PATH trades at 17.4x Forward P/E, 19.6x Trailing P/E, 0.41x PEG, and 3.7x EV/Revenue (21.1% FCF margin), whereas VRNS trades at 114.9x Forward P/E, 142.9x Trailing P/E, 7.38x PEG, and 8.2x EV/Revenue (16.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PATH (20.0% ROE) versus VRNS (-29.5% ROE) capital efficiency.
In options market volatility and institutional positioning, PATH carries 50.3% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.49x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.86β · 30% Vol realized risk). By comparison, VRNS carries 12.5% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.52β · 4% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.